Clinical trials: Cardiovascular Outcomes
Mitral Regurgitation, Mitral Valve Regurgitation
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR
The COAPT Continued Access Study (CAS) is an extension of the COAPT RCT under the same IDE (G120024). COAPT CAS was a single-arm, prospective, multicenter continued access registry that enrolled heart failure patients with…
- Trial name
- COAPT CAS (NCT07227675)
- Testing
- MitraClip® NT System
- Where
- 32 sites in United States
- Volunteers
- 162 people
- Sponsor
- Abbott Medical Devices
Pressure Ulcer, Foot Ulcer, Diabetic
Use of Santyl Within an Accountable Care Organization
This study is designed to assess the comparative effectiveness of SANTYL® versus standard of care in the treatment of pressure ulcers and diabetic foot ulcers within the continuum of care of an ACO.
- Trial name
- NCT02716519
- Testing
- Santyl, Standard Care
- Where
- United States
- Sponsor
- Smith & Nephew, Inc.
Atrial Fibrillation
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation
Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Xplorer systems during AF ablation procedures.
- Trial name
- COMPANION AI (NCT06056271)
- Testing
- AF Ablation
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- Volta Medical
Congestive Heart Failure
Relation of Non-invasively Measured Parameters to Clinical Outcomes in CHF Patients
Our aim is to assess whether changes in CO, CI and SVR as measured using the Biobeat wearable, wireless, non-invasive device during IV diuretic administration in an outpatient setting among CHF patients correlate with short-term…
- Trial name
- NCT04548024
- Testing
- Short term monitoring
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Biobeat Technologies Ltd.
Obesity, Cardiovascular Diseases
Naltrexone/Bupropion Cardiovascular Outcomes Study
The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse…
- Trial name
- NCT02638129
- Testing
- Naltrexone HCl/Bupropion HCl ER
- Where
- 139 sites in United States
- Volunteers
- 67 people
- Sponsor
- Orexigen Therapeutics, Inc
Overweight, Obesity
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends.
- Trial name
- SELECT-LIFE (NCT04972721)
- Testing
- No treatment given
- Where
- 38 sites in United States, Algeria and 22 more
- Volunteers
- 3,439 people
- Sponsor
- Novo Nordisk A/S
Atherosclerotic Cardiovascular Disease
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Italy)
This study will evaluate cardiovascular outcomes among individuals with clinically established atherosclerotic cardiovascular disease (ASCVD) who have not previously experienced a myocardial infarction (MI) or ischemic stroke.
- Trial name
- NCT07906132
- Where
- Italy
- Volunteers
- 93,000 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Multiple Electrode Aggregometry & Clopidogrel Resistance
Antiplatelet therapy with aspirin-clopidogrel reduces the risk of cardiovascular episodes after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD), Myocardial Infraction
- Trial name
- NCT01991093
- Where
- 3 sites in Greece
- Volunteers
- 280 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Type 2 Diabetes
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients.
- Trial name
- SPOTLIGHT (NCT07456774)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Ulcers, Diabetic Foot Wounds
Santyl Applications to Diabetic Foot Ulcers
The current trial examines the potential benefits of continuous 12 week treatment with Santyl, measured in terms of wound bed appearance.
- Trial name
- NCT02111291
- Testing
- Collagenase SANTYL® Ointment, Hydrogel (if needed) and foam dressing
- Where
- 25 sites in United States, Canada
- Volunteers
- 215 people
- Sponsor
- Healthpoint
Carotid Artery Disease
CHOICE: Carotid Stenting For High Surgical-Risk Patients
The purposes of this study is to 1) Provide additional information that the commercially available Abbott Vascular Carotid Stent Systems and Embolic Protection Systems can be used successfully by a wide range of physicians under…
- Trial name
- NCT00406055
- Testing
- RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
- Where
- United States
- Volunteers
- 18,855 people
- Sponsor
- Abbott Medical Devices
Diabetes Mellitus, Type 2
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to identify and evaluate the event rate of the composite endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for participants with Type 2 Diabetes mellitus (T2DM) and…
- Trial name
- NCT03249506
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 25,358 people
- Sponsor
- Janssen Research & Development, LLC
Arteriosclerosis, Hypercholesterolaemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk.
- Trial name
- NCT06008756
- Testing
- Enlicitide Decanoate
- Where
- 669 sites in United States, Argentina and 27 more
- Volunteers
- 14,550 people
- Sponsor
- Merck Sharp & Dohme LLC
Atherosclerosis
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways.
- Trial name
- XATOA (NCT03746275)
- Testing
- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid
- Where
- 18 sites in Argentina, Brazil and 16 more
- Volunteers
- 5,798 people
- Sponsor
- Bayer
Health, Subjective, Gastrointestinal Dysfunction
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease…
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- LIFE-HOUSE (NCT04005456)
- Testing
- Supplements and/or medical foods, Behavioral change support program, Food plan
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Heart Failure，Congestive
Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to…
- Trial name
- NCT03519477
- Testing
- Sano Patient Medication Profile
- Where
- United States
- Sponsor
- Precera Bioscience, Inc.
Diabetes Mellitus Type 2
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and…
- Trial name
- NCT01018173
- Testing
- taspoglutide
- Where
- 288 sites in United States, Australia and 23 more
- Volunteers
- 2,118 people
- Sponsor
- Hoffmann-La Roche
Heart Failure
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in…
- Trial name
- NCT07376265
- Where
- United States
- Volunteers
- 1,249 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin…
- Trial name
- NCT05102071
- Testing
- empagliflozin, metformin, sulfonylurea
- Where
- United States
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA).
- Trial name
- NCT01331837
- Testing
- Etanercept, Tocilizumab
- Where
- 428 sites in United States, Argentina and 29 more
- Volunteers
- 3,080 people
- Sponsor
- Hoffmann-La Roche